News Details

Neuropathic Pain Project Licensed

Signal Pharma has licensed a Kosterlitz Centre for Therapeutics programme for the treatment of neuropathic and inflammatory pain.

A second project from the Kosterlitz Centre for Therapeutics has been licensed by Signal Pharma: cannabinoid receptor type 1 (CB1) allosteric enhancers for the treatment of different types of pain, for which existing treatments (opiates and NSAIDs) are generally ineffective.  Signal has licensed a patent from the Universities of Toronto and Aberdeen featuring new compounds (CB1 PAMs) which have shown impressive potential in pre-clinical studies. 


In This Section

Search News

Search News

Browse by Month

2017

2017

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

2016

2015

2014

2013

2012

2011

2010